Heart failure and cardiac hypertrophy


Opinion statement

Left ventricular failure is the final common pathway for a wide spectrum of myocardial insults, including systemic hypertension and myocardial infarction. Although left ventricular hypertrophy is an adaptive response to pressure and volume overload, this process becomes maladaptive if left untreated and pathologic cardiac hypertrophy then becomes an important and independent risk factor for the development of heart failure. Despite its importance, the transition from hypertrophy to heart failure in humans is poorly understood. The focus of treatment should be prevention of heart failure and other cardiovascular events, such as stroke and atrial fibrillation. When heart failure is present, treatment with medical and device therapy is then focused on improving functional capacity, increasing survival, and preventing progression to end-stage heart failure.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pfeffer JM, Pfeffer MA, Mirsky I, et al.: Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A 1982, 79:3310–3314.PubMedCrossRefGoogle Scholar
  2. 2.
    Litwin SE, Katz SE, Weinberg EO, et al.: Serial echocardiographic Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Circulation 1995, 91:2642–2654.PubMedGoogle Scholar
  3. 3.
    Molkentin JD, Lu JR, Antos CL, et al.: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215–228.PubMedCrossRefGoogle Scholar
  4. 4.
    Rame JE, Ramilo M, Spencer N, et al.: Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol 2004, 93:234–237.PubMedCrossRefGoogle Scholar
  5. 5.
    Drazner MH, Rame JE, Marino EK, et al.: Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection within five years. The Cardiovascular Health Study. J Am Coll Cardiol 2004, 43:2207–2215.PubMedCrossRefGoogle Scholar
  6. 6.
    Klapholz M, Maurer M, Lowe AM, et al.: Hospitalization for Heart Failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004, 43:1432–1438.PubMedCrossRefGoogle Scholar
  7. 7.
    Vasan R, Larson MG, Benjamin EJ, et al.: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948–1955.PubMedCrossRefGoogle Scholar
  8. 8.
    Topol EJ, Traill TA, Fortuin NJ, et al.: Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985, 312:277–283.PubMedCrossRefGoogle Scholar
  9. 9.
    Levy D, Salomon M, Agostino RB, et al.: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994, 90:1786–1793.PubMedGoogle Scholar
  10. 10.
    Muiesan ML, Salvett M, Rizzoni D, et al.: Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995, 13:1091–1105.PubMedCrossRefGoogle Scholar
  11. 11.
    Verdecchia P, Schillaci G, Borgioni C, et al.: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998, 97:48–54.PubMedGoogle Scholar
  12. 12.
    Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615–1621.PubMedGoogle Scholar
  13. 13.
    Moser M, Herbert PR: Prevention of disease progression. LVH and CHF in hypertension treatment trials. J Am Coll Cardiol 1996, 27:1214–1217.PubMedCrossRefGoogle Scholar
  14. 14.
    Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289:2560–2572.PubMedCrossRefGoogle Scholar
  15. 15.
    Dahlof B, Devereux RB, Kjeldsen S, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Lancet 2002, 359:995–1003.PubMedCrossRefGoogle Scholar
  16. 16.
    Devereux RB, Dahlof B, Gerdts S, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456–1462.PubMedCrossRefGoogle Scholar
  17. 17.
    Adami GF, Cordera R, Camerini G, et al.: Recovery of insulin sensitivity in obese patients at short term after biliopancreatic diversion. J Surg Res 2003, 113:217–221.PubMedCrossRefGoogle Scholar
  18. 18.
    Molina A, Vendrell J, Gutierrez C: Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003, 13:615–621.PubMedCrossRefGoogle Scholar
  19. 19.
    Karason K, Wallentin I, Larsson B, et al.: Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. BMJ 1997, 315:912–916.PubMedGoogle Scholar
  20. 20.
    Ikonomidis I, Mazarakis A, Papadopoulos C, et al.: Weight loss after bariatric surgery improves aortic elastic properties and left ventricular function in individuals with morbid obesity: a three year follow-up study. J Hypertens 2007, 25:439–447.PubMedCrossRefGoogle Scholar
  21. 21.
    Dahlof B, Pennert K, Hansson L, et al.: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992, 5:95–110.PubMedGoogle Scholar
  22. 22.
    Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41–46.PubMedCrossRefGoogle Scholar
  23. 23.
    Carson P, Massie BM, Mckelvie R, et al.: The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005, 11:576–585.PubMedCrossRefGoogle Scholar
  24. 24.
    Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.PubMedCrossRefGoogle Scholar
  25. 25.
    Hjalmarson A, Goldstein S, Fagerberg B, et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000, 283:1295–1302.PubMedCrossRefGoogle Scholar
  26. 26.
    Pitt B, Remme W, Zannad F: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of CardiologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations